[Expert recommendations on the management of adverse reactions in pegylated interferon alpha therapy for chronic hepatitis B].

To provide a usage reference for clinicians with the increasing use of pegylated interferon alpha (PEG-IFN-ɑ) in treating chronic hepatitis B (CHB), the expert panel retrospectively summarized previous clinical experience and formulated expert recommendations based on the latest research findings and evidence-based medical data of this field, focusing on pre-treatment assessment to better assist clinicians in managing adverse reactions, help patients complete treatment courses, and maximize patient benefits.